REGENXBIO’s (RGNX) Outperform Rating Reaffirmed at Royal Bank of Canada

Royal Bank of Canada reiterated their outperform rating on shares of REGENXBIO (NASDAQ:RGNX) in a research note published on Tuesday,Benzinga reports. They currently have a $30.00 price target on the biotechnology company’s stock.

A number of other analysts have also weighed in on RGNX. Chardan Capital reaffirmed a “buy” rating and set a $52.00 target price on shares of REGENXBIO in a report on Wednesday, November 20th. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price target on shares of REGENXBIO in a report on Wednesday, January 15th. Morgan Stanley restated an “overweight” rating and set a $22.00 target price on shares of REGENXBIO in a research report on Friday, November 15th. Finally, Raymond James reaffirmed an “outperform” rating and issued a $18.00 price target on shares of REGENXBIO in a report on Thursday, October 10th. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat.com, REGENXBIO currently has a consensus rating of “Moderate Buy” and an average price target of $34.82.

REGENXBIO Stock Up 2.7 %

RGNX stock opened at $7.57 on Tuesday. The stock has a 50-day simple moving average of $8.58 and a two-hundred day simple moving average of $10.44. REGENXBIO has a twelve month low of $6.56 and a twelve month high of $28.80. The firm has a market capitalization of $375.02 million, a PE ratio of -1.50 and a beta of 1.28.

Institutional Investors Weigh In On REGENXBIO

A number of hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC grew its holdings in shares of REGENXBIO by 273.1% during the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 2,510 shares during the last quarter. FMR LLC grew its stake in shares of REGENXBIO by 166.8% during the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 1,656 shares during the last quarter. nVerses Capital LLC increased its holdings in shares of REGENXBIO by 183.3% in the third quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock worth $36,000 after buying an additional 2,200 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in shares of REGENXBIO by 64.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock valued at $100,000 after acquiring an additional 3,720 shares during the last quarter. Finally, Erste Asset Management GmbH purchased a new stake in REGENXBIO during the 3rd quarter valued at about $140,000. 88.08% of the stock is currently owned by institutional investors.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.